MedTrace Logo

Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

NCT00568035 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2009-01-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether QR-333 is safe and effective in the treatment of diabetic neuropathy as compared to placebo.

Conditions

  • Diabetic Neuropathy

Interventions

DRUG

QR-333

QR-333 or placebo will be applied three times a day for 12 weeks

Sponsors & Collaborators

  • Quigley Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Philip Raskin, MD · University of Texas, Southwestern Medical Center at Dallas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568035 on ClinicalTrials.gov